<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification and causes of jaundice or asymptomatic hyperbilirubinemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification and causes of jaundice or asymptomatic hyperbilirubinemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Classification and causes of jaundice or asymptomatic hyperbilirubinemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Namita Roy-Chowdhury, PhD, FAASLD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jayanta Roy-Chowdhury, MD, MRCP, AGAF, FAASLD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth B Rand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The normal serum bilirubin concentration in children and adults is less than 1 mg/dL (17 micromol/liter), less than 5 percent of which is present in conjugated form. The measurement is usually made using diazo reagents and spectrophotometry. Conjugated bilirubin reacts rapidly ("directly") with the reagents. The measurement of unconjugated bilirubin requires the addition of an accelerator compound and is often referred to as indirect bilirubin.</p><p>Jaundice is often used interchangeably with hyperbilirubinemia. However, a careful clinical examination cannot detect jaundice until the serum bilirubin is greater than 2 mg/dL (34 micromol/liter), twice the normal upper limit. The yellow discoloration is best seen in the periphery of the ocular conjunctivae and in the oral mucous membranes (under the tongue, hard palate). Icterus may be the first or only sign of liver disease; thus, its evaluation is of critical importance.</p><p>This topic will review the causes of asymptomatic hyperbilirubinemia. The diagnostic approach to the patient with jaundice and the causes of hyperbilirubinemia presenting in the neonatal period are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3620.html" rel="external">"Diagnostic approach to the adult with jaundice or asymptomatic hyperbilirubinemia"</a> and  <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a> and  <a class="medical medical_review" href="/z/d/html/3622.html" rel="external">"Bilirubin metabolism"</a>.)</p><p class="headingAnchor" id="H2973702584"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>For clinical purposes, the predominant type of bile pigments in the plasma can be used to classify hyperbilirubinemia into two major categories  (<a class="graphic graphic_table graphicRef55607" href="/z/d/graphic/55607.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unconjugated hyperbilirubinemia</strong> – Unconjugated hyperbilirubinemia is characterized by plasma elevation of predominantly unconjugated bilirubin due to the overproduction of bilirubin, impaired bilirubin uptake by the liver, or abnormalities of bilirubin conjugation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conjugated hyperbilirubinemia </strong>–<strong> </strong>In patients with conjugated hyperbilirubinemia, both unconjugated and conjugated bilirubin levels increase. Conjugated hyperbilirubinemia may be due to hepatocellular diseases, impaired canalicular excretion, defective reuptake of conjugated bilirubin, or biliary obstruction.</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DISORDERS ASSOCIATED WITH UNCONJUGATED HYPERBILIRUBINEMIA</span><span class="headingEndMark"> — </span>Three basic pathophysiologic mechanisms, overproduction of bilirubin, reduced bilirubin uptake, and impaired bilirubin conjugation, are mainly responsible for unconjugated hyperbilirubinemia. </p><p class="headingAnchor" id="H3"><span class="h2">Overproduction of bilirubin</span><span class="headingEndMark"> — </span>Bilirubin overproduction may result from excessive breakdown of heme derived from hemoglobin. Extravascular or intravascular hemolysis, extravasation of blood in tissues, or dyserythropoiesis are causes of enhanced heme catabolism. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conditions associated with bilirubin overproduction</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemolysis</strong> – The reticuloendothelial cells of the spleen, bone marrow, and liver are responsible for the increased extravascular destruction of erythrocytes, which occurs in most hemolytic disorders. These phagocytic mononuclear cells are rich in heme oxygenase and biliverdin reductase activities and rapidly degrade heme to bilirubin  (<a class="graphic graphic_figure graphicRef65197" href="/z/d/graphic/65197.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3622.html" rel="external">"Bilirubin metabolism"</a>.)</p><p></p><p class="bulletIndent2">With intravascular hemolysis, bilirubin is predominantly formed in the liver and the kidneys. Hemoglobin released in the circulation is bound to haptoglobin; this complex is internalized and degraded by hepatocytes. However, circulating haptoglobin may be depleted with massive hemolysis. In these cases, unbound hemoglobin is converted to methemoglobin, from which heme is transferred to hemopexin or to albumin, forming methemalbumin. Heme-hemopexin and methemalbumin are internalized by hepatocytes, where heme is degraded to bilirubin. A significant fraction of free methemoglobin is filtered by renal glomeruli after dissociation of the tetrameric globin to two dimers. Only the free (unbound) dimer is small enough to be filtered across the glomeruli. The heme moiety of filtered methemoglobin is largely degraded by tubular epithelial cells to bilirubin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dyserythropoiesis </strong>–<strong> </strong>In a variety of diseases including megaloblastic and sideroblastic anemias, severe iron deficiency anemia, erythropoietic porphyria, erythroleukemia, lead poisoning, and a rare disorder of unknown pathogenesis termed primary shunt hyperbilirubinemia, the incorporation of hemoglobin into erythrocytes is defective [<a href="#rid1">1,2</a>]. This leads to the degradation of a large fraction of unincorporated hemoglobin heme.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extravasation</strong> – When blood is extravasated into tissues, or pleural or peritoneal cavities, erythrocytes are phagocytosed by tissue macrophages that degrade heme to biliverdin, resulting in the sequential green and yellow discoloration of the skin overlying a hematoma. The biliverdin is immediately reduced to unconjugated bilirubin by the enzyme biliverdin reductase and is released into the plasma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pattern of bilirubin elevation based on the presence of underlying liver</strong> <strong>disease</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients</strong> <strong>without liver disease</strong> – In hemolysis, unconjugated bilirubin production can increase up to 10-fold. The canalicular excretion of bilirubin is the rate-limiting step in bilirubin elimination since hepatic conjugating capacity normally exceeds maximum bilirubin production. These relationships account for two findings at a steady state of maximum bilirubin production in patients with normal hepatic function. First, the serum bilirubin concentration will not exceed 4 mg/dL (68 micromol/liter) in patients with normal liver function [<a href="#rid3">3</a>] and second, the proportion of conjugated bilirubin in plasma (approximately 3 to 5 percent of the total) remains normal [<a href="#rid4">4</a>]. However, hemolysis can lead to severe mixed conjugated and unconjugated hyperbilirubinemia in patients who have even mild hepatic disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with coexisting liver disease</strong> – Most liver diseases affect canalicular excretion, resulting in the accumulation of both conjugated and unconjugated bilirubin in hepatocytes. In cholestatic states, the canalicular ATP-dependent organic anion pump, MRP2 (also termed ABCC2), is down-regulated. This may lead to upregulation of other forms of MRP, such as MRP3 (also termed ABCC3), in the contiguous membranes of the hepatocyte, resulting in active transport of unconjugated and conjugated bilirubin into the plasma [<a href="#rid5">5,6</a>]. Thus, plasma bilirubin accumulating in conditions resulting from a combination of bilirubin overload and liver disease is usually a mixture of unconjugated and conjugated bilirubin. In cases where there is an inherited deficiency of conjugation (eg, Gilbert syndrome), hemolysis causes almost pure unconjugated hyperbilirubinemia. The rate-limiting step in these patients is bilirubin glucuronidation, rather than canalicular excretion. (See  <a class="medical medical_review" href="/z/d/html/3578.html" rel="external">"Gilbert syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Impaired hepatic bilirubin uptake</span><span class="headingEndMark"> — </span>Impaired delivery of bilirubin to the liver and disorders of internalization of bilirubin by the hepatocyte result in reduced hepatic bilirubin uptake  (<a class="graphic graphic_figure graphicRef52393" href="/z/d/graphic/52393.html" rel="external">figure 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications (eg, rifamycin antibiotics, <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a>, flavaspidic acid, and bunamiodyl, a cholecystographic agent) can cause abnormal bilirubin uptake. The drug-induced defect usually resolves within 48 hours after discontinuation of the drug [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired bilirubin uptake at the sinusoidal surface of hepatocytes has been reported in some cases of Gilbert syndrome. (See  <a class="medical medical_review" href="/z/d/html/3578.html" rel="external">"Gilbert syndrome"</a>.). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congestive heart failure or portosystemic shunts (spontaneously occurring collaterals in cirrhosis or surgical shunts) reduce hepatic blood flow and the delivery of bilirubin to hepatocytes, resulting in predominantly unconjugated hyperbilirubinemia. In some patients with cirrhosis, the direct contact of plasma with the hepatocytes may be compromised due to capillarization of the sinusoidal endothelial cells (loss of fenestrae), resulting in a further reduction in bilirubin uptake [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Impaired bilirubin conjugation</span><span class="headingEndMark"> — </span>Reduced bilirubin conjugation as a result of a decreased or absent UDP-glucuronosyltransferase activity is found both in several acquired conditions and inherited diseases, such as Crigler-Najjar syndrome type I and II and Gilbert syndrome. (See  <a class="medical medical_review" href="/z/d/html/3578.html" rel="external">"Gilbert syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/3569.html" rel="external">"Crigler-Najjar syndrome"</a>.)</p><p>UGT activity toward bilirubin is modulated by various hormones. Hyperthyroidism and ethinyl estradiol, but not other oral contraceptives, inhibit bilirubin glucuronidation [<a href="#rid9">9</a>]. In comparison, the combination of progestational and estrogenic steroids results in increased enzyme activity. Bilirubin glucuronidation can also be inhibited by certain antibiotics (eg, novobiocin or <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> at serum concentrations exceeding therapeutic levels) and antiretroviral drugs (eg, <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a>) [<a href="#rid10">10</a>]. Reduced bilirubin glucuronidation by liver tissue has been reported in chronic persistent hepatitis, advanced cirrhosis, and Wilson's disease.</p><p class="headingAnchor" id="H14"><span class="h1">DISORDERS ASSOCIATED WITH CONJUGATED HYPERBILIRUBINEMIA</span><span class="headingEndMark"> — </span>Disorders with conjugated hyperbilirubinemia can be categorized according to their pathophysiology into those that are due to biliary obstruction (extrahepatic cholestasis), intrahepatic cholestasis, and hepatocellular injury  (<a class="graphic graphic_table graphicRef73409" href="/z/d/graphic/73409.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef71068" href="/z/d/graphic/71068.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H1049887428"><span class="h2">Cholestatic disorders</span><span class="headingEndMark"> — </span>In disorders associated with cholestasis, both conjugated and unconjugated bilirubin accumulate in serum and patients have elevations in alkaline phosphatase. There is a disproportionate elevation in the alkaline phosphatase compared with the serum aminotransferases. Tests of synthetic function (eg, albumin, prothrombin time) may be abnormal. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Patterns of liver test abnormalities'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Extrahepatic cholestasis/biliary obstruction</span><span class="headingEndMark"> — </span>In biliary obstruction, both conjugated and unconjugated bilirubin accumulate in serum. Bilirubin may be transported back to the plasma via an MRP group of ATP-consuming pumps [<a href="#rid6">6,11</a>]. The serum concentrations of conjugated bilirubin and alkaline phosphatase can be used as markers for hepatobiliary obstruction. Obstruction of biliary flow causes retention of conjugated bilirubin within the hepatocytes, where reversal of glucuronidation may take place. The unconjugated bilirubin formed by this process may diffuse or be transported back into the plasma. (See  <a class="medical medical_review" href="/z/d/html/3622.html" rel="external">"Bilirubin metabolism", section on 'Excretion of conjugated bilirubin'</a>.)</p><p>Differential diagnosis of conjugated hyperbilirubinemia due to biliary obstruction varies with age  (<a class="graphic graphic_table graphicRef73409" href="/z/d/graphic/73409.html" rel="external">table 2</a>). In adults, it includes cholelithiasis, intrinsic and extrinsic tumors, primary sclerosing cholangitis (PSC), parasitic infections, lymphoma, AIDS cholangiopathy, acute and chronic pancreatitis, and strictures after invasive procedures [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Intrahepatic cholestasis</span><span class="headingEndMark"> — </span>A number of intrahepatic disorders can lead to jaundice and an elevated serum alkaline phosphatase (in relation to serum aminotransferases)  (<a class="graphic graphic_table graphicRef71068" href="/z/d/graphic/71068.html" rel="external">table 3</a>). This presentation mimics that of biliary obstruction but the bile ducts are patent. </p><p class="headingAnchor" id="H249621210"><span class="h4">Inherited diseases</span><span class="headingEndMark"> — </span>Elevated levels of conjugated bilirubin may occur in inherited diseases such as Dubin-Johnson syndrome, Rotor syndrome, progressive familial intrahepatic cholestasis (PFIC), benign recurrent intrahepatic cholestasis (BRIC), and low phospholipid-associated cholelithiasis (LPAC). BRIC is seen in adolescents and adults, while LPAC presents mainly in young adults. (See  <a class="medical medical_review" href="/z/d/html/3584.html" rel="external">"Inherited disorders associated with conjugated hyperbilirubinemia"</a>.)</p><p>Disorders of fatty acid oxidation are characterized by episodes of metabolic decompensation, with hypoglycemia, liver dysfunction, and/or cardiomyopathy, triggered by fasting or intercurrent illness. These disorders may present at any age, from birth through adulthood. (See  <a class="medical medical_review" href="/z/d/html/6197.html" rel="external">"Metabolic myopathies caused by disorders of lipid and purine metabolism", section on 'Defects of beta-oxidation enzymes'</a>.)</p><p>Inherited diseases that cause conjugated hyperbilirubinemia that present during the neonatal period include Alagille syndrome, cystic fibrosis, and disorders of carbohydrate, lipid, or bile acid metabolism. These diseases are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>.)</p><p class="headingAnchor" id="H276458737"><span class="h4">Hepatitis</span></p><p class="bulletIndent1"><span class="glyph">●</span>Viral hepatitis – Viral hepatitis can present as a predominantly cholestatic syndrome with marked pruritus. Serologic evaluation is needed to distinguish this clinically from other causes of cholestasis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alcoholic hepatitis – Cholestasis with fever and leukocytosis is often the distinctive sign of alcoholic hepatitis [<a href="#rid13">13</a>]. The diagnosis should be strongly considered in the jaundiced patient with ethanol dependency, especially if the ratio of serum aspartate aminotransferase (AST) to alanine aminotransferase (ALT) exceeds 2.0 with the values being below 500 international units/L. (See  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic dysfunction-associated steatotic liver disease (MASLD) or MASLD-associated steatohepatitis (MASH) – Most patients with MASLD are asymptomatic, although some patients with MASH may complain of fatigue, malaise, and vague right upper abdominal discomfort [<a href="#rid14">14</a>]. A variety of conditions such as diabetes mellitus, morbid obesity, certain stomach and small bowel operations, and drugs can cause this disorder. (See  <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h4">Primary biliary cholangitis</span><span class="headingEndMark"> — </span>Primary biliary cholangitis typically presents with a cholestatic picture, though evidence of hepatocellular injury also exists. (See  <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"</a>.)</p><p class="headingAnchor" id="H21"><span class="h4">Drugs and toxins</span><span class="headingEndMark"> — </span>Drug-induced cholestasis can occur in a dose-related fashion (eg, alkylated steroids such as <a class="drug drug_general" data-topicid="9640" href="/z/d/drug information/9640.html" rel="external">methyltestosterone</a> and ethinyl estradiol) or as an idiosyncratic or allergic reaction in a minority of subjects (eg, <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>). Drugs and toxins causing hepatocellular injury may eventually present as a predominantly cholestatic syndrome [<a href="#rid15">15</a>]. </p><p>Certain plants used in "natural" medicines (eg, Jamaican bush tea) contain pyrrolizidine alkaloids, which may cause veno-occlusive disease of the liver [<a href="#rid16">16,17</a>] (see  <a class="medical medical_review" href="/z/d/html/3618.html" rel="external">"Hepatotoxicity due to herbal medications and dietary supplements"</a>). </p><p>Arsenic can cause cholestasis. It has recently gained increased attention because of its contamination of ground water in various parts of the world [<a href="#rid18">18</a>]. In addition to the well-known skin lesions, arsenic-contaminated drinking water has been associated with hepatic fibrosis and portal hypertension, usually without the formation of cirrhotic nodules.</p><p class="headingAnchor" id="H2713366812"><span class="h4">Parenteral nutrition</span><span class="headingEndMark"> — </span>Steatosis, lipidosis, and cholestasis are frequently encountered in patients receiving <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. This complication usually requires at least two to three weeks of therapy for the development of cholestasis [<a href="#rid19">19</a>]. The underlying illness, preexisting liver disease, hepatotoxic drugs, and the parenteral nutrition itself all may contribute to the cholestasis.</p><p><a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">Parenteral nutrition</a> promotes bacterial overgrowth in the small intestine, which in turn favors conditions well known to induce cholestasis such as translocation of intestinal endotoxins into the portal system [<a href="#rid20">20</a>], bacterial sepsis [<a href="#rid21">21</a>], and the formation of secondary bile acids (eg, lithocholic acid). Other contributing factors to cholestasis include biliary sludge, which occurs in all patients after six weeks of total parenteral nutrition (TPN), and hepatotoxic factors such as tryptophan degradation products and aluminum contaminants.</p><p class="headingAnchor" id="H22"><span class="h4">Sepsis and low perfusion states</span><span class="headingEndMark"> — </span>Bacterial sepsis is very often accompanied by cholestasis. Multiple factors including hypotension, drugs, and bacterial endotoxins are responsible for the jaundice in these patients [<a href="#rid22">22-24</a>]. On the other hand, hyperbilirubinemia can promote bacterial sepsis by increasing intestinal wall permeability and altering mucosal immunity [<a href="#rid25">25</a>]. Signs of cholestasis can also be found in other low perfusion states of the liver (heart failure, hypotension) and hypoxemia that is not profound enough to produce hepatic necrosis.</p><p class="headingAnchor" id="H23"><span class="h4">Infiltrative disorders</span><span class="headingEndMark"> — </span>Infiltrative processes of the liver (eg, amyloidosis, lymphoma, sarcoidosis, tuberculosis) can precipitate intrahepatic cholestasis. Paraneoplastic syndromes associated with malignancy can induce a reversible form of cholestasis (Stauffer syndrome) [<a href="#rid26">26</a>]. It has most commonly been described in association with renal cell carcinoma, though it has also been reported in patients with malignant lymphoproliferative diseases, gynecologic malignancies, and prostate cancer [<a href="#rid27">27,28</a>].</p><p class="headingAnchor" id="H3984636885"><span class="h4">Intrahepatic cholestasis of pregnancy</span><span class="headingEndMark"> — </span>Pruritus, usually occurring in the third trimester of pregnancy but sometimes earlier, typically heralds cholestasis, which may evolve into frank jaundice [<a href="#rid29">29</a>] and may be associated with an increased frequency of stillbirths and prematurity [<a href="#rid30">30</a>]. All the pathologic changes disappear following delivery (see  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy"</a>). It is of crucial importance to distinguish this entity from other potentially lethal liver disorders in pregnancy such as acute fatty liver and the HELLP (Hemolysis, Elevated Liver enzymes and Low Platelets) syndrome. (See  <a class="medical medical_review" href="/z/d/html/3619.html" rel="external">"Acute fatty liver of pregnancy"</a>.)</p><p class="headingAnchor" id="H697056814"><span class="h4">Other conditions associated with cholestasis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative jaundice</strong> – Jaundice occurs commonly in postoperative patients and is usually multifactorial in origin. Serum unconjugated bilirubin levels may increase because of blood transfusions, hematoma resorption, and hemolysis after heart surgery. Other contributing factors include sepsis, TPN, the administration of hepatotoxic drugs during surgery (such as halothane) [<a href="#rid31">31</a>], postoperative hypoxia, hypotension, or a newly acquired viral hepatitis [<a href="#rid32">32</a>]. Concomitant renal failure will exaggerate the hyperbilirubinemia. Surgery also can exacerbate a preexisting hemolytic disease or unmask an underlying genetic disorder (eg, Gilbert syndrome or glucose-6-phosphate dehydrogenase deficiency). (See  <a class="medical medical_review" href="/z/d/html/3604.html" rel="external">"Approach to the patient with postoperative jaundice"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organ transplantation</strong> – Intrahepatic cholestasis is common in transplant recipients (especially bone marrow and liver). These patients often require TPN and receive multiple potentially hepatotoxic drugs including immunosuppressive agents, which increase the susceptibility to infection. In addition to the skin and intestinal epithelium, other target sites of graft-versus-host disease in bone marrow transplants include the small interlobular bile ducts. The resulting inflammation and destruction lead to cholestasis. Intensive pretransplantation radiation and chemotherapy predisposes to the development of veno-occlusive disease of the liver, with cholestasis and liver failure.</p><p></p><p class="bulletIndent1">Signs of cholestasis after orthotopic liver transplantation may reflect preservation injury of the donor organ, an operative complication (bile leak, stricture) [<a href="#rid33">33</a>], and chronic allograft rejection ("vanishing bile duct syndrome"). In addition, cholestasis is occasionally the sole indicator of acute transplant rejection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>End-stage liver disease</strong> – With chronic hepatocellular injury, the biochemical profile changes over time as the liver injury progresses to cirrhosis and liver failure. The elevation of liver enzymes, a marker of active liver injury, becomes less prominent or even disappears. The primary manifestations at this time result from impaired hepatic protein synthesis (eg, hypoalbuminemia and a prolonged prothrombin time) and impaired excretory function, leading to jaundice. The hallmarks of end-stage liver disease and cirrhosis, regardless of its etiology, include jaundice with an elevation of both conjugated and unconjugated bilirubin as well as portal hypertension and decreased hepatic synthetic function.</p><p></p><p class="headingAnchor" id="H733432592"><span class="h2">Hepatocellular injury</span><span class="headingEndMark"> — </span>Hepatocellular injury is typically characterized by the release of intracellular proteins and small molecules into the plasma. Thus, in contrast to cholestatic syndromes, the elevations in serum conjugated and unconjugated bilirubin and bile salts are accompanied by elevations in the serum concentrations of hepatocellular enzymes, such as AST and ALT. Disorders frequently associated with hepatocellular jaundice are listed in the table  (<a class="graphic graphic_table graphicRef66083" href="/z/d/graphic/66083.html" rel="external">table 4</a>). However, many of these conditions can also present with cholestatic syndromes.</p><p class="headingAnchor" id="H27599859"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16983.html" rel="external">"Patient education: Jaundice in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/17219.html" rel="external">"Patient education: Gilbert syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification of hyperbilirubinemia</strong> – Based on the predominant type of bile pigments in the plasma, hyperbilirubinemia is classified into two major categories: conjugated and unconjugated  (<a class="graphic graphic_table graphicRef55607" href="/z/d/graphic/55607.html" rel="external">table 1</a>). Unconjugated hyperbilirubinemia is characterized by plasma elevation of predominantly unconjugated bilirubin due to the overproduction of bilirubin, impaired bilirubin uptake by the liver, or abnormalities of bilirubin conjugation. In patients with conjugated hyperbilirubinemia, <strong>both</strong> unconjugated and conjugated bilirubin levels increase. (See  <a class="medical medical_review" href="/z/d/html/3620.html" rel="external">"Diagnostic approach to the adult with jaundice or asymptomatic hyperbilirubinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms for unconjugated hyperbilirubinemia</strong> – Three basic pathophysiologic mechanisms, overproduction of bilirubin, reduced bilirubin uptake, and impaired bilirubin conjugation, are mainly responsible for unconjugated hyperbilirubinemia. Bilirubin overproduction may result from excessive breakdown of heme derived from hemoglobin. Extravascular or intravascular hemolysis, extravasation of blood in tissues, or dyserythropoiesis are causes of enhanced heme catabolism. (See <a class="local">'Disorders associated with unconjugated hyperbilirubinemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of conjugated hyperbilirubinemia</strong> – Disorders with conjugated hyperbilirubinemia can be categorized according to their pathophysiology as those due to biliary obstruction (extrahepatic cholestasis), intrahepatic cholestasis, or hepatocellular injury. </p><p></p><p class="bulletIndent1">In cholestatic disorders, both conjugated and unconjugated bilirubin accumulate in serum and patients have elevations in alkaline phosphatase. In patients with hepatocellular causes of hyperbilirubinemia, elevations in serum conjugated and unconjugated bilirubin and bile salts are accompanied by elevations in the serum concentrations of hepatocellular enzymes, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT).</p><p></p><p class="bulletIndent1">The differential diagnosis of extrahepatic and intrahepatic hyperbilirubinemia is summarized in the tables  (<a class="graphic graphic_table graphicRef73409" href="/z/d/graphic/73409.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef71068" href="/z/d/graphic/71068.html" rel="external">table 3</a>). (See <a class="local">'Disorders associated with conjugated hyperbilirubinemia'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">ROBINSON S, VANIER T, DESFORGES JF, SCHMID R. Jaundice in thalassemia minor: a consequence of "ineffective erythropoiesis". N Engl J Med 1962; 267:523.</a></li><li><a class="nounderline abstract_t">Israels G, Zipursky A. Primary shunt hyperbilirubinemia due to an alternate path of bilirubin production. Am J Med 1959; 27:693.</a></li><li><a class="nounderline abstract_t">Berk PD, Wolkoff AW, Berlin NI. Inborn errors of bilirubin metabolism. Med Clin North Am 1975; 59:803.</a></li><li><a class="nounderline abstract_t">Snyder AL, Satterlee W, Robinson SH, Schmid R. Conjugated plasma bilirubin in jaundice caused by pigment overload. Nature 1967; 213:93.</a></li><li><a class="nounderline abstract_t">Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001; 34:351.</a></li><li><a class="nounderline abstract_t">Jansen PL, Roskams T. Why are patients with liver disease jaundiced? ATP-binding cassette transporter expression in human liver disease. J Hepatol 2001; 35:811.</a></li><li><a class="nounderline abstract_t">Kenwright S, Levi AJ. Sites of competition in the selective hepatic uptake of rifamycin-SV, flavaspidic acid, bilirubin, and bromsulphthalein. Gut 1974; 15:220.</a></li><li><a class="nounderline abstract_t">SCHAFFNER F, POPER H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963; 44:239.</a></li><li><a class="nounderline abstract_t">Chowdhury JR, Chowdhury NR, Moscioni AD, et al. Differential regulation by triiodothyronine of substrate-specific uridinediphosphoglucuronate glucuronosyl transferases in rat liver. Biochim Biophys Acta 1983; 761:58.</a></li><li><a class="nounderline abstract_t">Roy-Chowdhury J, Roy-Chowdhury N, Listowsky I, Wolkoff AW. Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir. Clin Pharmacol Drug Dev 2017; 6:140.</a></li><li><a class="nounderline abstract_t">Rius M, Nies AT, Hummel-Eisenbeiss J, et al. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003; 38:374.</a></li><li><a class="nounderline abstract_t">Feng Y, Zhang S, Guo T, et al. Validity and safety of corticosteroids alone without biliary stenting for obstructive jaundice in autoimmune pancreatitis. Pancreatology 2020; 20:1793.</a></li><li><a class="nounderline abstract_t">Mendenhall CL, Anderson S, Weesner RE, et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984; 76:211.</a></li><li><a class="nounderline abstract_t">Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20:594.</a></li><li class="breakAll">Stricker BHCH. Drug-induced Hepatic Injury, Elsevier, Amsterdam 1993.</li><li><a class="nounderline abstract_t">Tandon BN, Tandon HD, Tandon RK, et al. An epidemic of veno-occlusive disease of liver in central India. Lancet 1976; 2:271.</a></li><li><a class="nounderline abstract_t">Tandon BN, Joshi YK, Sud R, et al. Follow-up of survivors of epidemic veno-occlusive disease in India. Lancet 1984; 1:730.</a></li><li><a class="nounderline abstract_t">Bagla P, Kaiser J. India's spreading health crisis draws global arsenic experts. Science 1996; 274:174.</a></li><li><a class="nounderline abstract_t">Allardyce DB. Cholestasis caused by lipid emulsions. Surg Gynecol Obstet 1982; 154:641.</a></li><li><a class="nounderline abstract_t">van Deventer SJ, ten Cate JW, Tytgat GN. Intestinal endotoxemia. Clinical significance. Gastroenterology 1988; 94:825.</a></li><li><a class="nounderline abstract_t">Zimmerman HJ, Fang M, Utili R, et al. Jaundice due to bacterial infection. Gastroenterology 1979; 77:367.</a></li><li><a class="nounderline abstract_t">Fuchs M, Sanyal AJ. Sepsis and cholestasis. Clin Liver Dis 2008; 12:151.</a></li><li><a class="nounderline abstract_t">Hojo M, Sano N, Takikawa H. Effects of lipopolysaccharide on the biliary excretion of bile acids and organic anions in rats. J Gastroenterol Hepatol 2003; 18:815.</a></li><li><a class="nounderline abstract_t">Bolder U, Ton-Nu HT, Schteingart CD, et al. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology 1997; 112:214.</a></li><li><a class="nounderline abstract_t">Welsh FK, Ramsden CW, MacLennan K, et al. Increased intestinal permeability and altered mucosal immunity in cholestatic jaundice. Ann Surg 1998; 227:205.</a></li><li><a class="nounderline abstract_t">Dourakis SP, Sinani C, Deutsch M, et al. Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma. Eur J Gastroenterol Hepatol 1997; 9:311.</a></li><li><a class="nounderline abstract_t">Walther MM, Johnson B, Culley D, et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 1998; 159:718.</a></li><li><a class="nounderline abstract_t">Karakolios A, Kasapis C, Kallinikidis T, et al. Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. Clin Gastroenterol Hepatol 2003; 1:480.</a></li><li><a class="nounderline abstract_t">Reyes H. Review: intrahepatic cholestasis. A puzzling disorder of pregnancy. J Gastroenterol Hepatol 1997; 12:211.</a></li><li><a class="nounderline abstract_t">Shaw D, Frohlich J, Wittmann BA, Willms M. A prospective study of 18 patients with cholestasis of pregnancy. Am J Obstet Gynecol 1982; 142:621.</a></li><li><a class="nounderline abstract_t">Dale O, Brown BR Jr. Clinical pharmacokinetics of the inhalational anaesthetics. Clin Pharmacokinet 1987; 12:145.</a></li><li><a class="nounderline abstract_t">Faust TW, Reddy KR. Postoperative jaundice. Clin Liver Dis 2004; 8:151.</a></li><li><a class="nounderline abstract_t">Stratta RJ, Wood RP, Langnas AN, et al. Diagnosis and treatment of biliary tract complications after orthotopic liver transplantation. Surgery 1989; 106:675.</a></li></ol></div><div id="topicVersionRevision">Topic 3615 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14492944" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Jaundice in thalassemia minor: a consequence of "ineffective erythropoiesis".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Primary shunt hyperbilirubinemia due to an alternate path of bilirubin production</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/806753" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Inborn errors of bilirubin metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Conjugated plasma bilirubin in jaundice caused by pigment overload</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11481620" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11738110" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Why are patients with liver disease jaundiced? ATP-binding cassette transporter expression in human liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4842968" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sites of competition in the selective hepatic uptake of rifamycin-SV, flavaspidic acid, bilirubin, and bromsulphthalein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13976646" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Capillarization of hepatic sinusoids in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6416299" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Differential regulation by triiodothyronine of substrate-specific uridinediphosphoglucuronate glucuronosyl transferases in rat liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263463" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12883481" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33097432" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Validity and safety of corticosteroids alone without biliary stenting for obstructive jaundice in autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6421159" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2656500" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nonalcoholic steatohepatitis: a study of 49 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2656500" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nonalcoholic steatohepatitis: a study of 49 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/59849" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : An epidemic of veno-occlusive disease of liver in central India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6143056" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Follow-up of survivors of epidemic veno-occlusive disease in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8927976" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : India's spreading health crisis draws global arsenic experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7071699" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cholestasis caused by lipid emulsions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276576" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Intestinal endotoxemia. Clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Jaundice due to bacterial infection</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18242502" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sepsis and cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12795754" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effects of lipopolysaccharide on the biliary excretion of bile acids and organic anions in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8978362" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9488518" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased intestinal permeability and altered mucosal immunity in cholestatic jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9096437" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9474133" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15017648" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9142637" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Review: intrahepatic cholestasis. A puzzling disorder of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7065033" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A prospective study of 18 patients with cholestasis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3555939" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical pharmacokinetics of the inhalational anaesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15062198" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Postoperative jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2799642" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diagnosis and treatment of biliary tract complications after orthotopic liver transplantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
